All Drug Targets articles – Page 19
-
Newsp53's role in ulcerative colitis and its progression to cancer
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
-
NewsGPNMB: a potential therapeutic agent for cardiovascular disease
Researchers reveal that GPNMB could be an effective therapeutic agent to improve cardiac function and prevent heart failure.
-
ArticleHarnessing the CD24/Siglec-10 pathway: immunotherapy innovation
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
-
ArticleCell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
-
News
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
-
ArticleAI-driven drug discovery: insights from Cresset
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
-
NewsLargest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
-
News
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
-
NewsBCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
-
Article’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings. ...
-
NewsPancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
-
NewsMechanism linking obesity to inflammation uncovered
This study is first to demonstrate with statistical certainty that human visceral adipose tissue accumulated in the abdominal cavity secretes more extracellular vesicles.
-
NewsCreating retroelement-based epigenetic clocks
Targeting the epigenetic states of specific retroelements in the human genome could mitigate the biological effects of ageing.
-
NewsTransforming disease diagnosis with new nanoparticles
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
-
NewsOvercoming the limitations of existing AI models
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
-
NewsGenetic variants influencing SR B-ALL relapse risk identified
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
-
ArticleOut of the lab and into patients: targeting APE1/Ref-1
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes ...
-
ArticleRestoring TERT to attenuate ageing hallmarks
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
-
WebinarUnprecedented fragment-based screening using Spectral Shift for GPCRs
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
-
NewsSpinal muscular atrophy: searching for a cure
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.